Kongsaengdao Subsai, Maneeton Narong, Maneeton Benchalak
Division of Neurology, Department of Medicine, Rajavithi Hospital, Department of Medical Services, Public Health Ministry, Bangkok, Thailand.
Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand.
Neuropsychiatr Dis Treat. 2018 Apr 26;14:1119-1124. doi: 10.2147/NDT.S152252. eCollection 2018.
The short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients. However; the long-term study has not been published.
The aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients.
A 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period.
A total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains ( < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections ( = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study.
The Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study.
泰国的颈部肌张力障碍（CD）患者接受阿泊肉毒素A（Abo - BTX A）和新肉毒素A（Neu - BTX A）治疗后的短期生活质量（QoL）已得到研究。然而，长期研究尚未发表。
本研究的目的是确定CD患者在2年内接受8次Abo - BTX A注射后与健康相关的生活质量（HRQoL）的长期改善情况。
进行了一项为期2年的前瞻性研究，以评估CD患者在2年治疗期内每隔3个月接受8次Abo - BTX A注射前后的QoL，通过HRQoL进行测量。在治疗前后使用颈部肌张力障碍影响量表 - 58（CDIP - 58）问卷评估疾病特异性HRQoL。使用医学结局简表36项健康调查（SF - 36）评估总体HRQoL，同时使用流行病学研究中心抑郁量表（CES - D）问卷评估抑郁症筛查情况。在治疗前以及2年期间每次下次注射前每3个月发放一次SF - 36和CES - D问卷。
2013年1月至2015年12月共纳入20例CD患者。长期注射Abo - BTX A后，CDIP - 58在所有领域均显示出显著改善（<0.001）。然而，评估总体HRQoL的SF - 36中只有活力领域在长期注射后显示出显著改善（=0.037）。本研究中所有患者均无抑郁症患病率（CES - D评分<20）。
在2年期间每隔3个月注射Abo - BTX A可改善评估疾病特异性HRQoL的CDIP - 58评分，以及提高总体HRQoL的活力领域得分。本研究中没有患者患抑郁症。
